Skip to main content

Table 3 Combination index (CI) for cell viability in GBM cell lines U-251 MG and U-343 MG treated with BKM120/PQR309 and URMC-099 (n = 3)

From: Synergism between the phosphatidylinositol 3-kinase p110β isoform inhibitor AZD6482 and the mixed lineage kinase 3 inhibitor URMC-099 on the blockade of glioblastoma cell motility and focal adhesion formation

BKM120 (μM) PQR309 (μM) URMC-099 (μM) CI* in U-251 MG cells CI in U-343 MG cells
BKM120 + URMC-099 PQR309 + URMC-099 BKM120 + URMC-099 PQR309 + URMC-099
0.5 1 0.75 1.3989 ± 0.2163 1.5254 ± 0.3801 4.7114 ± 0.2524 1.1346 ± 0.0512
1 2 1.5 1.4334 ± 0.1484 1.4664 ± 0.2958 3.6418 ± 0.8218 1.9790 ± 0.0174
2 4 3 1.1565 ± 0.2646 0.8072 ± 0.0409 2.9486 ± 0.6378 1.7963 ± 0.2530
3 6 4.5 0.8357 ± 0.0579 0.6518 ± 0.0092 1.2952 ± 0.5308 0.8334 ± 0.1518
4 8 6 1.1241 ± 0.1438 1.0504 ± 0.1408 0.9371 ± 0.0928 0.8804 ± 0.0166
5 10 7.5 1.6589 ± 0.2057 1.8739 ± 0.1506 1.1621 ± 0.0186 1.1876 ± 0.0811
  1. * Data were presented as mean ± S.E.M. CI < 0.9 indicates synergistic effects; CI > 1.1 indicates antagonistic effects; CI between 0.9 and 1.1 indicates additive effects